GB00BYX3WZ24
© ACCESS Newswire
22.12.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares
News Preview
LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.The FCA has notified the Company that the admission hearing has been schedule...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
18.12.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC - Issue of Equity
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. LO...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.11.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, UK / ACCESS Newswire / November 19, 2025 / This announcement is an advertisement and not a prospectus. Neither this announcement nor anyth...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
29.10.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards
News Preview
DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team LONDON, UK / ACCESS Newswire / October 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the independent Data Safety Monitoring Board ("DSMB") ove...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
06.10.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.MD A...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
News Preview
Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares are admitted to the equity shares (transition) category of the Official List, announces its unaud...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
News Preview
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in EstoniaFirst Potential Near-Term Revenue Opportunity LONDON / ACCESS Newswire / September 23, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has signed a Letter of Intent ("LOI"...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety
News Preview
Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September 17, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the third patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit
News Preview
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the upcoming DCNY Summit, taking place in Washington, DC on 18 September 2025 and in New York on 22 Septe...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
HEMO
LISTED
LSE
Made Scientific and Hemogenyx Pharmaceuticals Announce Technology Transfer and Manufacturing Partnership to Advance HG-CT-1, an Autologous CAR-T Cell Therapy for Acute Myeloid Leukemia
News Preview
PRINCETON, N.J. and NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of hematologic malignancies and other l...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Manufacturing Partnership with Made Scientific
News Preview
Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made Scientific to Advance HG-CT-1 CAR-T Therapy CITY OF LONDON, GB / ACCESS Newswire / September 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce a manufacturing partnership with Made Scientific, a leading U.S.-based cell therapy contract development and m...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
05.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. LON...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
03.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. LON...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.09.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Issu...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.08.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender
News Preview
LONDON, UK / ACCESS Newswire / August 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory auditor, it intends to re-appoint PKF Littlejohn LLP as external auditor for the financial year ending December 2025 onwards. This will coincide with...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
26.08.2025
HEMO
LISTED
LSE
Hemogenyx raises £570,000 and Director's Dealing
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. LON...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.08.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC - Third Patient Treated with HG-CT-1 CAR-T Therapy
News Preview
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS Newswire / August 15, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that the third patient has been success...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.07.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £250,000 and Director's Dealing
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Hemo...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.07.2025
HEMO
LISTED
LSE
Hemogenyx Awarded Grant
News Preview
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing LONDON, UK / ACCESS Newswire / July 16, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been awarded a $120,000 G-Rex® grant from ScaleReady, in collaboration with Wilson Wolf Manufacturing and Cell Rea...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.06.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Clearance to Proceed with Pediatric Expansion
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Regu...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
03.06.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Hemo...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
03.06.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC - Second Patient Passes Initial Safety Tests
News Preview
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / June 3, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the second patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric Anti...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
14.05.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol
News Preview
Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML LONDON, UNITED KINGDOM / ACCESS Newswire / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has filed an amendment to the clinical protocol for its ongoing Phase I clinical trial of HG-CT-1 to include pediatric patients with r...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.05.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. LON...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.05.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy
News Preview
LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ("R/R AML&q...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.04.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Final Results
News Preview
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.c...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
03.04.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report
News Preview
Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML LONDON, UK / ACCESS Newswire / April 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has submitted its Annual Report to the U.S. Food and Drug Administration (FDA) under the active Investigational New Drug (IND) application...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
31.03.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
News Preview
LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2025 consists of 4,093,539 ordinary shares of 1p each, none of which are held in treasury. There...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.03.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces First Patient Safety
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE I...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.03.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
News Preview
Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.03.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
News Preview
Institutional backing of £709,200 for continuing Phase 1 Clinical Trials LONDON, UNITED KINGDOM / ACCESS Newswire / March 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ("Hemogenyx Pharmaceuticals" or the "Company") is pleased to announce that it was approached by an institution wishing to make an investment into the C...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.02.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.02.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
News Preview
LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.THIS ANNOUNCEMENT CONTAINS INSIDE IN...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.01.2025
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000
News Preview
LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares") at a price of 340p per share (the "Placing"). One institutional investor has subscribed for the Placing Shares and has al...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.12.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Opening of First Clinical Site
News Preview
Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I TrialPatient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults LONDON, UK / ACCESSWIRE / December 30, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is plea...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.12.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing
News Preview
Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
News Preview
Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, wishes to provide a further update on the admission of t...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed
News Preview
Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1 LONDON, UNITED KINGDOM / ACCESSWIRE / December 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, is pleased to announce the su...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.12.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery Update
News Preview
Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce a breakthrough in its development of a novel method for delivering Chimeric Bait Receptors ("CBR&q...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.11.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting
News Preview
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New Articles of Association LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group focused on developing new therapies...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.11.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
News Preview
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB)of th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.11.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
News Preview
Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical group focused on developing new therapies for bl...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.10.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening
News Preview
Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.10.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
News Preview
Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments f...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.09.2024
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
News Preview
LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month per...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
